Entry

D03455                      Drug

Name

Cetuximab (USAN/INN);
Cetuximab (genetical recombination) (JAN);
Erbitux (TN)

Product

ERBITUX (ImClone LLC)

Sequence

(Heavy chain)
QVQLKQSGPG LVQPSQSLSI TCTVSGFSLT NYGVHWVRQS PGKGLEWLGV IWSGGNTDYN
TPFTSRLSIN KDNSKSQVFF KMNSLQSNDT AIYYCARALT YYDYEFAYWG QGTLVTVSAA
STKGPSVFPL APSSKSTSGG TAALGCLVKDYFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
(Light chain)
DILLTQSPVI LSVSPGERVS FSCRASQSIG TNIHWYQQRT NGSPRLLIKY ASESISGIPS
RFSGSGSGTD FTLSINSVES EDIADYYCQQ NNNWPTTFGA GTKLELKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H95, H146-H202, H222-L214, H228-H'228, H231-H'231, H263-H323, H369-H427, H'22-H'95, H'146-H'202, H'222-L'214, H'263-H'323, H'369-H'427, L23-L88, L134-L194, L'23-L'88, L'134-L'194)

Type

Peptide

Class

Antineoplastic
DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03162  EGFR inhibitor

Remark

Therapeutic category:

4291

ATC code:

L01FE01

Product:

D03455<JP/US>

Efficacy

Antineoplastic, Anti-epidermal growth factor receptor antibody

Disease

Squamous cell carcinoma of the head and neck [DS:H02420]
Colorectal cancer (K-Ras wild type, EGFR-expressing) [DS:H00020]
Colorectal cancer (BRAF mutation positive) [DS:H00020]

Comment

Monoclonal antibody

Target

EGFR [HSA:1956] [KO:K04361]

Pathway

hsa04010

MAPK signaling pathway

hsa04012

ErbB signaling pathway

hsa05200

Pathways in cancer

Interaction

Structure map

map07045

Antineoplastics - protein kinase inhibitors

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
     L01FE01 Cetuximab
      D03455  Cetuximab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Cetuximab
    D03455  Cetuximab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D03455  Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN)
Drug groups [BR:br08330]
Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03162  EGFR inhibitor
     D03455  Cetuximab
Drug classes [BR:br08332]
Antineoplastic
  DG03162  EGFR inhibitor
   D03455  Cetuximab
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    EGFR
     D03455  Cetuximab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D03455
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D03455
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D03455
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D03455
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
  D03455

Other DBs

CAS:	205923-56-4

PubChem:

17397595

NIKKAJI:

J2.240.829A